Polaryx Therapeutics has received Orphan Drug Designation From the European Medicines Agency (EMA) for PLX-200 for the treatment of Neuronal Ceroid Lipofuscinosis.    Neuronal Ceroid Lipofuscinosis is a group of autosomal recessive neurodegenerative lysosomal storage disorders. This disorder is caused by cellular accumulation of abnormal auto-fluorescent lipoproteins, resulting in deterioration of neurons in both the brain and retina. Because many patients suffer from vision loss, severe...